Breast Cancer Treatment Drugs Lapatinib for Anti Cancer
|10-19 20-49 50-99 100+|
|FOB Unit Price:||US $2 US $5 US $8 US $10|
|Purchase Qty. (gram)||FOB Unit Price|
|Port:||Hong Kong, Hong Kong|
|Payment Terms:||T/T, Western Union, Money Gram, Bitcoin|
- Model NO.: CAS 231277-92-2
- Customized: Customized
- Suitable for: Adult
- Purity: >99%
- CAS: 231277-92-2
- MW: 581.0575
- Transport Package: as Requires
- Origin: China
- Powder: Yes
- Certification: GMP, HSE, ISO 9001, USP, BP
- State: Solid
- Product Name: Lapatinib, Tykerb, Lapatinib Ditosylate
- Mf: C29h26clfn4o4s
- Trademark: Biopharmchem
- Specification: Pharmaceutical Grade
- HS Code: 2934999090
Breast cancer treatment drugs Lapatinib for anti cancer
Product name:Lapatinib,Tykerb,lapatinib ditosylate
Lapatinib (INN), used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
Lapatinib is used for:
Lapatinib is a protein-tyrosine kinase inhibitor. It works by preventing the growth of cancer cells.
Treating certain types of advanced or metastatic breast cancer. It is used in combination with another medicine (capecitabine or letrozole). It may also be used for other conditions as determined by your doctor.
Like many small molecule tyrosine kinase inhibitors, lapatinib is regarded as well tolerated. The most common side effects reported are diarrhea, fatigue, nausea and rashes. In clinical studies elevated liver enzymes have been reported. QT prolongation has been observed with the use of lapatinib ditosylate but there are no reports of torsades de pointes. Caution is advised in patients with hypokalaemia, hypomagnesaemia, congenital long QT syndrome, or with coadministration of medicines known to cause QT prolongation. In combination with capecitabine, reversible decreased left ventricular function are common (2%).